Biolife Solutions (BLFS) Cash & Equivalents (2010 - 2026)

Biolife Solutions (BLFS) has 17 years of Cash & Equivalents data on file, last reported at $22.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 65.91% year-over-year to $22.8 million in Q1 2026; TTM through Mar 2026 was $22.8 million, a 65.91% decrease from a year earlier, with the FY2025 full-year figure at $33.0 million, down 63.91% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $22.8 million, down from $33.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for BLFS reached as high as $91.5 million in Q4 2024 and fell as low as $19.1 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $33.5 million across 5 years, with a median of $27.0 million in 2022.
• Across the five-year window, Cash & Equivalents sank 72.17% in 2022 and surged 228.14% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $19.4 million in 2022, then soared by 43.48% to $27.9 million in 2023, then jumped by 228.14% to $91.5 million in 2024, then tumbled by 63.91% to $33.0 million in 2025, then plunged by 30.92% to $22.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $22.8 million in Q1 2026, $33.0 million in Q4 2025, and $29.5 million in Q3 2025.